Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer, with promising clinical activity against other HR defective tumors including breast and prostate cancers. Three PARP inhibitors have been FDA approved, while another two have shown promising activity and are in late stage development. Nonetheless, both primary and secondary resistance to PARP inhibition have led to treatment failure, and the development of predictive biomarkers and the ability to identify and overcome mechanisms of resistance is vital for optimization of its clinical utility. Additionally, there has been evidence that PARP inhibition may have a therapeutic role beyond HR deficient tumors which warrants further investigation, both as single agent and in combination with other therapeutic modalities like cytotoxic chemotherapy, radiation, targeted therapy and immunotherapy. With new strategies to overcome resistance and expand its therapeutic utility, PARP inhibitors are likely to become a staple in our armamentarium of drugs in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, resistance inevitably emerges during its clinical application, which can lead to cancer progression and reduced survival rates, posing a substantial challenge in clinical management [31].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · cited 1×
“Phase I studies subsequently demonstrated good safety and tolerability up to a dose of 400 mg twice daily, with dose limiting toxicities of grade 4 thrombocytopenia and grade 3 somnolence, and also showed early signals of antitumor activity with a response rate of up to 46% in heavily pre-treated BRCA1/2-mutant cancer…”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · cited 1×
“DSBs are repaired through 2 major pathways, the high fidelity HR pathway, and the more error-prone non-homologous end-joining (NHEJ) pathway [7].”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 1×
“PARP inhibitors profoundly sensitize cancer cells to DNA damaging agents and act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA1/2 mutations [2].”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“A systemic screen of cancer cell lines with a large panel of drugs revelaed that Ewing’s sarcoma cells harboring the EWSR10FLI1 gene translocation was exquisitely sensitive to PARP inhibitors [48].”
BackgroundNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451 · cited 1×
“In this study, patients with platinum-sensitive disease were included regardless of germline BRCA1/2 mutation and HR deficiency status, while results were stratified to investigate role of HR deficiency biomarkers for response [27].”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“for patients with platinum sensitive compared to platinum resistant disease [16,17].”
BackgroundTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 2×
“Emerging evidence also suggests that in addition to the catalytic action of PARP inhibitors leading to synthetic lethality in HR deficient tumors, PARP inhibitors also causes trapping of PARP1 and PARP2, forming PARP-DNA complexes with increased cytotoxicity leading to increased cell killing [9].”
BackgroundDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · cited 4×
“Besides ovarian cancer, olaparib has also shown potential efficacy in other cancers involving both germline and somatic BRCA1/2 mutations, including that of prostate, breast, gastric and pancreatic cancer [3,22,23].”
BackgroundInfluentialOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“Over the past decade, convincing evidence has emerged regarding the role of PARP inhibitors in BRCA1/2 mutant cancers including ovarian, breast and prostate cancers [3,4,16,19].”
BackgroundTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379 · cited 1×
“, through BRCA1/2 mutations, double-stranded DNA (dsDNA) repair is impaired, leading to cells becoming increasingly reliant on PARP as a primary mechanism of DDR and in turn, making them exquisitely sensitive to PARP inhibition [8] (Figure 1).”
BackgroundRegulation of DNA repair throughout the cell cycle
Branzei, D., & Foiani, M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2351 · Cited by 1,228 · cited 1×
“Thus, inhibitors of cell cycle checkpoint proteins in cancer cells may lead to circumvention of cell cycle delay resulting in increased sensitivity to DNA-damage induced apoptosis [59].”
BackgroundSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · cited 2×
“The phase II ARIEL2 study confirmed that rucaparib prolonged PFS in patients with platinum-sensitive recurrent ovarian cancers, and led to FDA approval of rucarapib [25].”
BackgroundRole of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174 · cited 1×
“Once DDR is completed, PARP autoPARylates and is released from the repaired DNA strand [6].”
BackgroundTelli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136 · cited 1×
“Interestingly, on top of PFS, this score was also found to predict for pathologic complete response rates [28].”
Background(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121 · cited 1×
“It has been more than 35 years since the role of adenosine-diphosphate(ADP)-ribose and its effects was first described by Durkacz and colleagues [1], and our understanding of poly-(ADP-ribose) polymerase (PARP) inhibition has greatly expanded since.”
BackgroundGelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · cited 1×
“Contrarily, there are tumors without known mutations in DNA damage repair genes that are also sensitive to and may benefit from PARP inhibitors [5].”
BackgroundSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · cited 1×
“Interestingly, such mutations were observed not only in patients with BRCA1/2-mutant breast cancers that were resistant to PARP inhibitors, but also patients who had platinum resistant disease [33].”
BackgroundResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 1×
“Studies from independent groups have shown that restoration of BRCA1/2 function occurred in cell lines treated with PARP inhibitors through secondary mutations that restored the ORF through formation of new isoforms encoding the RAD51 binding domain at the C-terminus [32].”
BackgroundFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010 · cited 1×
“Phase I studies subsequently demonstrated good safety and tolerability up to a dose of 400 mg twice daily, with dose limiting toxicities of grade 4 thrombocytopenia and grade 3 somnolence, and also showed early signals of antitumor activity with a response rate of up to 46% in heavily pre-treated BRCA1/2-mutant cancer…”
BackgroundPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · cited 1×
“In vitro and in vivo models of breast cancer have also shown that PARP inhibition inactivates of GSK3β, which in turn upregulate PD-L1 expression, providing evidence to support combination of PARP inhibitors and immune checkpoint blockade for treatment of breast cancer [75].”
BackgroundStereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756 · cited 1×
“Drug Company IC50/nM Relative PARP Trapping Potency [9,11] Predominant Toxicities”
BackgroundABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629 · cited 1×
“In BRCA1/2 mutant cancers that have been treated with PARP inhibitors, increased expression of MDR1 genes have been observed, leading to increased expression of Pgp and a resultant higher rate of drug efflux, diminishing the therapeutic intracellular effect of PARP inhibitors [42].”
BackgroundTargeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618 · cited 1×
“Synergistic cytotoxicity has been described when drugs that inhibit cell cycle regulators are combined with PARP inhibition, and multiple early phase studies have been initiated where drugs inhibiting cell cycle regulators like Wee1, ATR and CHK are being combined with PARP inhibitors [60].”
Background53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 603
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601 · cited 1×
“Inhibition of the PI3K/AKT/mTOR pathways in combination with PARP inhibitors have also showed synergistic activity in BRCA1/2-mutant breast cancers, with pharmacoydynamic studies showing corresponding downstream effects [66].”
BackgroundLiu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585 · cited 1×
“0005), and this is currently being further explored in a phase III study [72].”
BackgroundNorquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547 · cited 1×
“The combination of PARP inhibitors with platinum agents has been tested in recurrent platinum sensitive ovarian cancers with the combination of olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy demonstrating significantly improved progression-free survival versus paclitaxel plus carboplatin…”
BackgroundARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522 · cited 1×
“Besides germline BRCA1/2-mutant cancers, there has been increasing evidence that PARP inhibitors may have a role in somatic BRCA1/2-mutant cancers, or cancers associated with HR deficiency [3,25], and more recently, possibly even tumors deficient in chromatin regulation like cancers with ARID1A mutations [76].”
BackgroundLoss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514 · cited 1×
“Besides mutations that restore the ORF of the RAD51 binding domain, development of resistance could also occur due to partial restoration of HR through somatic loss of 53BP1, a mechanism that is unique to BRCA1 mutations and not BRCA2 deletions [35].”
BackgroundKaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465 · cited 1×
“The rationale for combination could be attributed to observation of increased levels of H2AX, suggesting an accumulation of dsDNA breaks requiring PARP activity for DNA repair, possibly accounting for the exquisite sensitivity of tumor cells to doublet therapy of PARP and PI3K inhibition [67].”
BackgroundLedermann, J. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 450
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 401
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390 · cited 1×
“Pgp is encoded by the MDR1 gene, and upregulation of Pgp expression has been known to be a mechanism of resistance to chemotherapy [41].”
Backgroundde Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 387 · cited 1×
“In a phase I, two-part study of talazoparib in treatment refractory tumors, including germline BRCA1/2 mutant and other selected sporadic cancers, single agent antitumor activity was observed in BRCA1/2 mutation-associated breast and ovarian cancers, and also patients with pancreatic and small cell lung cancers whose…”
BackgroundDevelopment of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329 · cited 1×
“More importantly, there is a need to embrace the use of novel adaptive trial design to allow for validation of mechanistic hypotheses, and to allow for cohort expansion in tumor types that show early signs of response [77].”
BackgroundCao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 309 · cited 1×
“The 53BP1 protein is a NHEJ factor that when deleted, promotes damaged DNA ends to produce recombinogenic ssDNA competent for HR [36,37].”
BackgroundKim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290 · cited 2×
“Besides ovarian cancer, olaparib has also shown potential efficacy in other cancers involving both germline and somatic BRCA1/2 mutations, including that of prostate, breast, gastric and pancreatic cancer [3,22,23].”
BackgroundCTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285 · cited 1×
“There have been data indicating that BRCA1/2 deficient cancers express higher levels of neoantigens and are therefore likely to be more immunogenic, and preclinical studies showed that a combination of PARP inhibition with a CTLA-4 antibody showed synergistic activity in BRCA1/2 mutant ovarian cancer [74].”
BackgroundTurning ecology and evolution against cancer
Korolev, K. S., Xavier, J. B., & Gore, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3712 · Cited by 277 · cited 1×
“Tumor cells undergo complex evolutionary mechanisms not unlike the Darwinian evolution of species, and exploitation of such evolutionary models may allow for more efficacious cell killing effect [43,44].”
BackgroundHopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270 · cited 1×
“The potency of PARP trapping differs amongst different PARP inhibitors and does not seem to correlate with its catalytic effect, potentially accounting for differential potency in some PARP inhibitors such as talazoparib [10] (Table 1).”
BackgroundBRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair
Bunting, S. F., Callén, E., Kozak, M. L., Kim, J. M., Wong, N., López-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.02.015 · Cited by 252 · cited 1×
“The 53BP1 protein is a NHEJ factor that when deleted, promotes damaged DNA ends to produce recombinogenic ssDNA competent for HR [36,37].”
BackgroundSen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., Redwood, A. B., Fan, Y. H., Li, L., Glisson, B. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3409 · Cited by 194 · cited 3×
“Similar results have also been shown in SCLC, providing preclinical proof-of-concept supporting initiation of clinical studies for combination treatment in patients with platinum sensitive or resistant relapsed SCLC [65].”
ResultInfluentialBalmaña, J., Tung, N. M., Isakoff, S. J., Graña, B., Ryan, P. D., Saura, C., Lowe, E. S., Frewer, P., Winer, E., Baselga, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu187 · Cited by 177 · cited 1×
“PARP inhibitors in combination strategies with chemotherapy like cisplatin or caelyx was found to be more tolerable with promising antitumor activity, and would benefit from further studies to verify preliminary findings [45,46].”
ResultChoy, E., Butrynski, J. E., Harmon, D. C., Morgan, J. A., George, S., Wagner, A. J., D’Adamo, D., Cote, G. M., Flamand, Y., Benes, C. H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-813 · Cited by 176 · cited 1×
“A non-randomised phase II trial that was subsequently conducted showed that treatment of metastatic Ewing’s sarcoma with olaparib was safe and well tolerated, although single agent activity appeared to be minimal [49].”
BackgroundDrew, Y., Ledermann, J., Hall, G., Rea, D., Glasspool, R., Highley, M., Jayson, G., Sludden, J., Murray, J., Jamieson, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.41 · Cited by 162 · cited 3×
“Nonetheless, combination strategies with chemotherapy have been limited by toxicities, predominantly that of myelosuppression, and strategies to overcome these toxicities have included the use of intermittent dosing schedules of PARP inhibitors [24].”
InfluentialBortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors
Neri, P., Ren, L., Gratton, K., Stebner, E., Johnson, J., Klimowicz, A., Duggan, P., Tassone, P., Mansoor, A., Stewart, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363911 · Cited by 157 · cited 1×
“Using a similar approach in multiple myeloma, bortezomib has been shown to induce “BRCAness” through depletion of nuclear ubiquitin and abrogation of H2AX polyubiquitylation, leading to sensitization of cells to treatment with veliparib [73].”
BackgroundCombined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
Karnak, D., Engelke, C. G., Parsels, L. A., Kausar, T., Wei, D., Robertson, J. R., Marsh, K. B., Davis, M. A., Zhao, L., Maybaum, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1038 · Cited by 156 · cited 1×
“The combination of Wee1 and PARP inhibitors to radiosensitize pancreatic cancer cells has been tested in xenograft models, and shown to produce significant radiosensitisation with a 13-day delay in tumor volume doubling and complete eradication of 20% of tumors compared to radiation alone [61].”
BackgroundMo, W., Liu, Q., Lin, C. C.-J., Dai, H., Peng, Y., Liang, Y., Peng, G., Meric-Bernstam, F., Mills, G. B., Li, K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1772 · Cited by 136 · cited 1×
“Besides PI3K inhibitors, combination of PARP inhibitor and everolimus, an mTOR inhibitor, has shown similar efficacy in BRCA1/2-proficient triple negative breast cancers [70].”
BackgroundHenneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte-Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500223112 · Cited by 126 · cited 1×
“In the context of reducing drug efflux, AZD2461, a PARP inibitor that is a poor P-glycoprotein substrate, has been developed and has shown increased response compared to olaparib in preclinical breast cancer models [47].”
BackgroundExploiting ecological principles to better understand cancer progression and treatment
Basanta, D., & Anderson, A. R. A. (2013) · Interface Focus · doi:10.1098/rsfs.2013.0020 · Cited by 126 · cited 1×
“Tumor cells undergo complex evolutionary mechanisms not unlike the Darwinian evolution of species, and exploitation of such evolutionary models may allow for more efficacious cell killing effect [43,44].”
BackgroundChan, N., & Bristow, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0527 · Cited by 120 · cited 1×
“Combinations of antiangiogenic agents like cediranib and bevacizumab with PARP inhibitors have also been tested on the basis of preclinical studies suggesting that hypoxemic states can suppress HR due to downregulation of HR repair proteins, thus inducing “BRCAness” and sensitizing cells to PARP inhibition [71].”
BackgroundDe, P., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014) · Neoplasia · doi:10.1593/neo.131694 · Cited by 110 · cited 1×
“Similar studies in BRCA-wild type, PI3K-mutant triple negative breast cancer cell lines showed that combination therapy of PARP and PI3K inhibition with carboplatin blocked tumor growth in mouse xenograft models, with decrease in tumor cell proliferation and tumor induced angiogenesis [69].”
ResultMiddleton, M. R., Friedlander, P. A., Hamid, O., DAUD, A. I., Plummer, R., Falotico, N., Chyla, B., Jiang, F., McKeegan, E. M., Mostafa, N. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv308 · Cited by 96 · cited 2×
“Besides platinum salts, other DNA alkylating agents that have been tested extensively include temozolamide, which has been combined with veliparib and tested in patients with melanoma and glioblastomas (GBM), albeit with limited success [29,52].”
BackgroundResultBarazzuol, L., Jena, R., Burnet, N. G., Meira, L. B., Jeynes, J. C. G., Kirkby, K. J., & Kirkby, N. F. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-65 · Cited by 96
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Ordóñez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero-Martín, D., García-Macías, M. D. C., Sevillano, V., Alonso, D., Pascual-Pasto, G., San-Segundo, L., Vila-Ubach, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4303 · Cited by 95 · cited 1×
“Combination strategies with other drugs such as trabectadin used in treatment of Ewing’s sarcoma have showed promising results in a preclinical setting, and clinical trials are currently underway to validate these findings in patients [50].”
BackgroundNowsheen, S., Bonner, J. A., & Yang, E. S. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.084 · Cited by 93
Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
González-Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X.-S., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0230 · Cited by 92 · cited 1×
“In a preclinical study of prostate cancer, PARP inhibition apperars to trigger a p53-dependent cellular senescence in PTEN-deficient prostate cancer cell lines, and combination of PARP and PI3K inhibitors had synergistic inhibition of growth in both in vitro and in vivo models [68].”
BackgroundRamalingam, S. S., Blais, N., Mazieres, J., Reck, M., Jones, C. M., Juhasz, E., Urban, L., Orlov, S., Barlesi, F., Kio, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3069 · Cited by 81 · cited 1×
“veliparib has also been tested in other cancers such as non-small cell lung cancer (NSCLC) and melanoma, although results have been disappointing [29,30].”
ResultYarchoan, M., Myzak, M. C., Johnson, B. A., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77 · cited 1×
“Besides ovarian cancer, olaparib has also shown potential efficacy in other cancers involving both germline and somatic BRCA1/2 mutations, including that of prostate, breast, gastric and pancreatic cancer [3,22,23].”
BackgroundWilson, R. H., Evans, T. J., Middleton, M. R., Molife, L. R., Spicer, J., Dieras, V., Roxburgh, P., Giordano, H., Jaw-Tsai, S., Goble, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.36 · Cited by 77 · cited 1×
“PARP inhibitors in combination strategies with chemotherapy like cisplatin or caelyx was found to be more tolerable with promising antitumor activity, and would benefit from further studies to verify preliminary findings [45,46].”
ResultRobins, H. I., Zhang, P., Gilbert, M. R., Chakravarti, A., de Groot, J., Grimm, S. A., Wang, F., Lieberman, F. S., Krauze, A. V., Trotti, A., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1966-z · Cited by 76 · cited 1×
“Besides platinum salts, other DNA alkylating agents that have been tested extensively include temozolamide, which has been combined with veliparib and tested in patients with melanoma and glioblastomas (GBM), albeit with limited success [29,52].”
BackgroundHirai, T., Shirai, H., Fujimori, H., Okayasu, R., Sasai, K., & Masutani, M. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02268.x · Cited by 68 · cited 1×
“Preclinical studies have demonstrated an improvement in tumor response to radiation when PARP inhibitors were introduced, possibly through induction of S phase arrest through DDR and delay in dsDNA processing by PARP inhibition, leading to further sensitisation of cells to radiation [54].”
BackgroundRNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
Nakada, S., Yonamine, R. M., & Matsuo, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1057 · Cited by 62
Wurster, S., Hennes, F., Parplys, A. C., Seelbach, J. I., Mansour, W. Y., Zielinski, A., Petersen, C., Clauditz, T. S., Münscher, A., Friedl, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6947 · Cited by 55
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.
Yin, Y., Shen, Q., Zhang, P., Tao, R., Chang, W., Li, R., Xie, G., Liu, W., Zhang, L., Kapoor, P., et al. (2017) · PubMed · Cited by 51
Coleman, R. L., Swisher, E. M., Oza, A. M., Scott, C. L., Giordano, H., Lin, K. K., Konecny, G. E., Tinker, A., O'Malley, D. M., Kristeleit, R. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5540 · Cited by 33
Lemasson, B., Wang, H., Galbán, S., Li, Y., Zhu, Y., Heist, K., Tsein, C., Chenevert, T. L., Rehemtulla, A., Galbán, C. J., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2015.11.014 · Cited by 30
Farago, A. F., Drapkin, B. J., Charles, A., Yeap, B. Y., Heist, R. S., Azzoli, C. G., Jackman, D. M., Barbie, D. A., Choy, E., Sequist, L. V. D., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct048 · Cited by 9
Snedeker, J. C., Burleson, T. M., Tibes, R., & Porter, C. C. (2014) · Blood · doi:10.1182/blood.v124.21.3621.3621 · Cited by 1 · cited 1×
“Similar studies looking at combination of Wee1 and PARP inhibitors in acute myeloid leukemic cells have also shown synergistic inhibition of cell growth, leading to enhanced DNA damage and induction of apoptosis [62].”
Background
Cited by
van den Heerik, A. S. V. M., Horeweg, N., de Boer, S. M., Bosse, T., & Creutzberg, C. L. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001822 · Cited by 197
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
“Strategies to bypass this resistance may imply alternate dosing of PARP inhibitors or combined administration with platinum derivatives [346].”
BackgroundDNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovicova, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 168
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 150
Metadata
- Authors
- Lim, J., & Tan, D. S. P.
- Affiliations
- National University Cancer Institute, Singapore (SG)
- Corresponding author
- Tan, David S. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-08-22
- Volume
- 9
- Issue
- 8
- Pages
- 109
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC5575612
- OpenAlex
- W2750488721
- Cited by
- 52
- References
- 78
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 5 · 2020: 5 · 2019: 12 · 2018: 7 · 2017: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- PARP inhibitors, synthetic lethality, homologous recombination deficiency, BRCA mutations, drug resistance mechanisms, predictive biomarkers, ovarian cancer, breast cancer, prostate cancer, combination therapy, immunotherapy, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.